Kymera Reports 25–35% FeNO Drops, Starts IRF5 Dosing with $1.6B Runway
Kymera Therapeutics reported Phase Ib atopic dermatitis data showing 25–35% FeNO reductions and 55% in an asthma subgroup, supporting Phase IIb dosing of its STAT6 degrader. The company also began dosing its IRF5 degrader in healthy volunteers and holds $1.6 billion cash with runway to 2029 as it pivots to immunology.
1. Phase Ib Atopic Dermatitis Data
An open-label trial in 22 moderate-to-severe AD patients tested 100 mg and 200 mg doses of KT-621, demonstrating strong STAT6 degradation and FeNO reductions of 25–35% in AD patients and roughly 55% in those with comorbid asthma, with biomarker and clinical signals comparable or superior to dupilumab.
2. IRF5 Degrader Clinical Dosing
Kymera initiated dosing of its IRF5 degrader in healthy volunteers, with initial safety and pharmacodynamic data expected in the second half of 2026 and a proof-of-concept study in lupus to follow, supported by clean 6- and 9-month toxicology findings and upcoming partner milestones.
3. Strategic Pivot and Financial Runway
Over the past 12–18 months, Kymera has shifted its emphasis from oncology to immunology and inflammation, advancing six IMiD degrader programs into the clinic and securing $1.6 billion in cash to fund operations into 2029.
4. Upcoming Phase IIb Trial Timelines
Enrollment for the Phase IIb atopic dermatitis trial is expected to finish in 2026 with data by mid-2027, while the enriched eosinophilic asthma study—targeting high FeNO and eosinophil patients using FEV1 endpoints—is slated to report in late 2027.